Partial
Mostly Aligned
Patient Risk:
Low
Summary
The provided content focuses on HYZAAR fetal toxicity/pregnancy warnings and is largely consistent with the supplied label excerpts. However, the overall user-provided claims mainly concern “Hyzaar discounts” and generic/coupon logistics, for which there is no FDA label support in the supplied prescribing information; additionally, the response presented multiple pregnancy-related statements without addressing the other off-topic claims, indicating substantial mismatch to the intended evaluation scope.
Category Scores
Accurate Statements
HYZAAR can cause fetal harm when administered during pregnancy; use during the second and third trimesters reduces fetal renal function and increases fetal and neonatal morbidity and death.
Label 5.1 Fetal Toxicity and 8.1 Pregnancy Risk Summary
Oligohydramnios can occur and is associated with fetal lung hypoplasia and skeletal deformations.
Label 5.1 Fetal Toxicity
Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.
Label 5.1 Fetal Toxicity (neonatal adverse effects examples)
When pregnancy is detected, discontinue HYZAAR as soon as possible.
Label 5.1 Fetal Toxicity and 8.1 Pregnancy
Thiazides cross the placental barrier and are associated with fetal or neonatal jaundice and thrombocytopenia.
Label 5.1 Fetal Toxicity
Thiazides should not be used to treat hypertension in pregnant women; use for other indications in pregnancy should be avoided.
Label 5.1 Fetal Toxicity (hydrochlorothiazide pregnancy discussion) / 8.1 Pregnancy section content provided
Unsupported Statements
Hyzaar is a combination product of losartan and hydrochlorothiazide.
Not supported or evaluated against the supplied label excerpts provided (only fetal toxicity/pregnancy sections were included).
Statements about Hyzaar discounts: sources (pharmacy cash-price programs, manufacturer programs, third-party coupon sites), comparison to generic pricing, insurance/coupon stacking, redemption rules, and advice to ask pharmacist about cash price/coupon application.
Not supported by the supplied FDA label excerpts (pregnancy/fetal toxicity only).
DrugPatentWatch.com tracks patent and exclusivity information and can contextualize pricing/competition changes.
Not supported by the supplied prescribing information excerpts.
Generic availability and cost-reduction strategies (e.g., switching to generic losartan/hydrochlorothiazide as the biggest way people reduce cost).
Not supported by the supplied prescribing information excerpts.
Contradictions
Important Omissions
The response omitted label-specific pregnancy counseling instructions present in the provided label excerpt (e.g., advise childbearing-age females about consequences of exposure, discuss options if planning pregnancy, and report pregnancies to physicians).
Importance:
Moderate
If evaluating the broader list of discount/generic/coupon claims, none of those topics are addressed using the supplied label content; this is a material mismatch to the supplied FDA-label section scope.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The supported portion (pregnancy/fetal toxicity warnings and discontinuation guidance) aligns with the provided label and is safety-relevant. However, the broader set of discount/coupon/cost-advice claims lacks label support and could mislead if treated as FDA-label guidance, though it does not directly alter HYZAAR fetal toxicity content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Substantial portion of the evaluated claims concerns pricing/discount/coupon logistics and generic availability, which are not supported by the provided FDA label excerpts (fetal toxicity/pregnancy only). The pregnancy-related statement set is largely consistent with label wording, but is somewhat condensed and omits specific patient counseling instructions provided in the label excerpt.
Suggested Improvement
Limit claims strictly to what is present in the supplied prescribing information excerpts (pregnancy/fetal toxicity). If pregnancy counseling is mentioned, include the specific label counseling elements (advise childbearing-age females, discuss options for those planning pregnancy, and report pregnancies promptly). Remove or re-scope pricing/coupon and patent/competition claims since they are not label-supported.